PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.

ABSTRACT: Gastrointestinal (GI) malignancies are the most prevalent tumors worldwide, with increasing incidence and mortality. Although surgical resection, chemotherapy, radiotherapy, and molecular targeted therapy have led to significant advances in the treatment of GI cancer patients, overall survival is still low. Therefore, alternative strategies must be identified to improve patient outcomes. In the tumor microenvironment, tumor cells can escape the host immune response through the interaction of PD-1 and PD-L, which inhibits the function of T cells and tumor-infiltrating lymphocytes while increasing the function of immunosuppressive T regulatory cells. The use of an anti-PD-1/PD-L blockade enables reprogramming of the immune system to efficiently identify and kill tumor cells. In recent years,

SUBMITTER: Long J 

PROVIDER: S-EPMC5543600 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature